Genmab A/S (NASDAQ:GMAB) Sets New 1-Year High - Here's Why

Key Points

• Genmab A/S reached a new **52-week high** of $33.63, with the stock last trading at $33.22, reflecting significant trading volume of 945,117 shares.
• Analysts have upgraded Genmab's ratings with several firms issuing **strong-buy** and **buy** ratings, leading to a consensus rating of **"Moderate Buy"** and an average price target of $40.80.
• The company reported earnings of **$0.54 per share**, exceeding estimates by $0.15, and has set its FY 2025 guidance while forecasting **1.45 earnings per share** for the current year.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s share price hit a new 52-week high on Monday . The stock traded as high as $33.63 and last traded at $33.22, with a volume of 945117 shares changing hands. The stock had previously closed at $33.56.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wall Street Zen raised Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Truist Financial increased their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Zacks Research upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Weiss Ratings reiterated a "hold (c)" rating on shares of Genmab A/S in a report on Saturday, September 27th. Finally, Guggenheim raised Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

Genmab A/S Stock Down 0.8%

The company's 50-day simple moving average is $25.84 and its 200 day simple moving average is $22.46. The company has a market capitalization of $21.38 billion, a P/E ratio of 16.75, a P/E/G ratio of 1.89 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Foresight Group Ltd Liability Partnership acquired a new stake in shares of Genmab A/S in the first quarter worth $954,000. Vident Advisory LLC acquired a new position in shares of Genmab A/S during the first quarter valued at about $242,000. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 1,465.3% in the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after buying an additional 31,343 shares during the period. Fifth Third Bancorp grew its position in Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock worth $825,000 after buying an additional 6,015 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Genmab A/S by 377.5% in the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company's stock valued at $77,000 after acquiring an additional 2,941 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.